Eli Lilly price target lowered to $825 from $975 at Cantor Fitzgerald

Cantor Fitzgerald analyst Carter Gould lowered the firm’s price target on Eli Lilly (LLY) to $825 from $975 and keeps an Overweight rating on the shares. The firm believes the orforglipron Phase 3 obesity data coming in below expectations and the semaglutide benchmarks creates a “show-me-story” around the launch. A resolution may not occur until late 2026, the analyst tells investors in a research note.